Company intelligence / Profile preview
Hyperion DeFi
- Ownership
- Public · HYPD
- Employees
- ~13
- Development stage
- Other
Overview
Hyperion DeFi is pivoting from ophthalmic device and drug development (notably the Optejet delivery system and drug/device combinations) to a novel public company model centered on holding and staking digital assets (HYPE token). Its lead device, Optejet, is aiming for FDA registration in September 2025. Main therapeutic products (e.g., Mydcombi, clobetasol propionate ophthalmic suspension) have US regulatory clearances for targeted indications, and new formulation co-development is ongoing.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeBiologicDevice
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $38.8M
- Total revenue
- $813.5K
- Enterprise value
- $38.1M
Beyond the preview
Go deeper on Hyperion DeFi.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hyperion DeFi.